Related Experiment Videos
Venous thromboembolism: anticoagulation, lysis, or filter?
1Department of Surgery, Medical University of South Carolina, Charleston 29425.
Journal of the South Carolina Medical Association (1975)
|August 1, 1991
Summary
Standard anticoagulation is the primary treatment for deep venous thrombosis (DVT) and pulmonary emboli. Thrombolytic therapy and percutaneous caval interruption offer alternative options for select patients with contraindications or recurrent events.
Area of Science:
- Vascular Medicine
- Thrombosis Management
Background:
- Deep venous thrombosis (DVT) and pulmonary emboli (PE) are significant clinical challenges.
- Current literature emphasizes standard anticoagulation as the primary treatment modality.
Purpose of the Study:
- To review and summarize the established and alternative treatment strategies for DVT and PE.
- To identify patient populations that may benefit from advanced therapeutic interventions.
Main Methods:
- Review of existing medical literature and clinical experience regarding DVT and PE treatment.
- Analysis of the efficacy and indications for anticoagulation, thrombolytic therapy, and caval interruption.
Main Results:
- Standard anticoagulation with heparin and Coumadin remains the mainstay treatment for DVT and PE.
- Thrombolytic agents like urokinase or streptokinase are beneficial for selected patients.
- Percutaneous caval interruption is optimal for preventing PE in patients with anticoagulation contraindications or recurrent emboli.
Conclusions:
- Anticoagulation is the first-line therapy for venous thromboembolism.
- Thrombolysis and caval interruption are valuable adjuncts for specific high-risk patient groups.
- Careful patient selection is crucial for optimizing outcomes with alternative therapies.